PATENT CLAIM ANALYSIS

Application Number: 16311913
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "218100"]

Abstract:
The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.

Claim (Index 1):
A mutant genomic sequence comprising a sequence as set forth in SEQ ID NO:1 in which at least one site of fixation for miR-4279 is restored.

Metadata:
- Claim Count in Document: 22.0
- Percentile: 98.0
- Lexical Diversity: 1.6988
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['11843256', '15212804', '10302547', '11453344', '09839796']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6383978567528947
- 35 USC 102 Novelty (BERT): 0.4760372627230672
- Combined Prediction Score: 0.622161797349912
- Mean Citation Score: 122.16320159999998
- Max Citation Score: 127.703804
- Similarity Product: 89.79142510616518

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test